Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17613748 | 1.00 | CTSV (0.55) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL7850065 | 0.94 | CTSV (0.56) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16315647 | 0.89 | CTSV (0.47) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL13225259 | 0.85 | CTSV (0.48) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16315591 | 0.84 | CTSV (0.64) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8248171 | 0.84 | CTSV (0.64) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL16315592 | 0.82 | CTSV (0.65) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL8248669 | 0.82 | CTSV (0.65) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL17613786 | 0.82 | CTSV (0.71) | CTSVCTSLCTSBELANECMA1 | |
| SCHEMBL12142687 | 0.80 | F13A1 (0.41) | F13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919478-B1 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8119602-B2 | Administration of HCV protease inhibitors in combination with food to improve bioavailability | SCHERING CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1730110-B9 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7772178-B2 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7635694-B2 | For treating hepatitis C and related disorders such as HIV, AIDS (Acquired Immune Deficiency Syndrome) | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | CTSV 32/4885CTSL 65/4885CTSB 193/4885 |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | CTSV 35/4885CTSL 79/4885CTSB 90/4885 |
| US-20070232527-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | CTSV 1/4885CTSL 12/4885CTSB 14/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | CTSV 33/4885CTSL 109/4885CTSB 199/4885 |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | LPXN, SLC5A11, F12 | CTSV 1420/4885CTSL 3343/4885CTSB 3661/4885 |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | PRSS1, PRSS3, HPN | CTSV 126/4885CTSL 486/4885CTSB 344/4885 |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | CTSV, AKR1B1, AKR1A1 | CTSV 1/4885CTSL 12/4885CTSB 14/4885 |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | CTRL, PEPD, PRCP | CTSV 10/4885CTSL 106/4885CTSB 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.